Palmitoylethanolamide, PEA, Palmitoylethanolamide Flake, Cas No.544-31-0, Dietary Supplement

 

Our factory has been producing Palmitoylethanolamide powder for many years. As the earliest and biggest manufacturer of PEA, CAS: 544-31-0 palmitoylethanolamide bulk powder, we have FDA register No, and we also have ISO on it.

For the qualtity, our Palmitoylethanolamide powder was tested in USA lab and our assay of PEA is very high, could be 99%.

 

Palmitoylethanolamide Bulk Powder (CAS 544-31-0) Synonym

N-(2-HYDROXYETHYL)HEXADECANAMIDE; N-HEXADECANOYLETHANOLAMINE; PEAPALMIDROL; Palmidrol

● CAS: 544-31-0

● EC No.: 208-867-9

● MF: C18H37NO2

● MW: 299.49

 

 

Test Item	Specification	Results
Appearance	White To Light-yellow Crystalline Solid	Complies
Melt Point (℃)	93-98℃	96.2℃
Coliforms	10cfu/g	Not Detected
E.Coli	Negative	Complies
Salmonella	Negative	Complies
Staphylococcus	Negative	Complies
Total Plate Count	10cfu/g Max	Not Detected
Yeast And Molds	10cfu/g Max	Not Detected
Heavy Metals	Lead: 3ppm Max	Complies
	Mercury: 0.1ppm Max	Complies
	Cadmium: 1ppm Max	Complies
	Arsenic: 0.5ppm Max	Not Detected
Residue Solvents	No Solvents Exist	Complies
Particle Size	100% ≤30μm	Complies
Purity	≥98%	99.3%

 

● Packing: 100g/bag; 500g/bag; 1kg/bag; 25kg/drum

● Recommended storage method: Store in a cool, dry and ventilated place.

● Recommended storage temperature: 2-8°C

● Product usage: Dietary supplements, anti-inflammatory agents

 

 

 

 

 

1: What is Palmitoylethanolamide (CAS 544-31-0)?

Palmitoylethanolamide, produced in the body, is a natural painkiller ingredient in the endogenous fatty acid amide category and synthesized within your own body. We call it endogenous. Palmitoylethanolamide pea powder is widely applied in sports nutrition supplements and joint health formulas worldwide, especially in the United States, Australia, UK, Canada, Netherlands, Belgium, Italy, France, Germany, Brazil, India, Swissland, Russia and many other countries.

 

Palmitoylethanolamide:

Its mechanism of action was discovered by the Nobel laureate professor Rita Levi-Montalcini, and its chemical structure is as follows:

 

 

PEA is a special natural substance; Nobel Prize holder LeviMontalcini discovered its effect and she also described its value in treating chronic infections and pains. Following her discovery, hundreds of scientific studies have been carried out, which elaborate on her research results.

 

● PEA is a natural substance with a long-term effect that corresponds with the natural healing power of our body.

● PEA has been described in more than 700 scientific publications.

● PEA was described in 1957 for the first time.

● PEA has already been used by more than a million people all over the world.

● PEA can be used in combination with other products without any problems.

● PEA is a natural substance.

● PEA is produced in our body.

● PEA can be found in food such as meat, eggs, soybeans and peanuts.

 

Our patent synthesis method to ensure our raw Palmitoylethanolamide is usually in flake form, the only one company in the world who could make this kind flake Palmitoylethanolamide. Our patent synthesis method make our Palmitoylethanolamide do not have any chemical solvents residue because we did not use any chemicals solvents to produce our Palmitoylethanolamide. So, GIHI Chemicals Palmitoylethanolamide is healthier for human.

 

Palmitoylethanolamide is practically insoluble in water and poorly soluble in most other aqueous solvents. In the workd market,there are four main dosage formulations of palmitoylethanolamide:

● Capsules

● Soft gels

● Tablet

● Cream

 

Palmitoylethanolamide food sources

 

Soy lecithin, soybean, egg yolk, peanut (Arachis hypogaea), and Medicago sativa are the top food sources. However, the calculating weight unit is ng/g (nanogram/gram). 6700 ng/g is equal to 6.7mg/kilo, this means that only 6.7mg PEA is in 1 kilo of soybean. The concentration of palmitoylethanolamide in natural foods are too low to meet our daily need. So,that is why we need to take some PEA from PEA capsule or other containing PEA formulation products.

 

1: Our factory has been producing Palmitoylethanolamide(PEA) for many years. As the earliest and biggest manufacturer of PEA ,CAS:544-31-0,we have FDA register No,and we also have ISO on it.

For the qualtity,our PEA was tested in USA lab and our assay of PEA is very high,could be 99%.

 

We have 3 grades of Palmitoylethanolamide(PEA),CAS:544-31-0:

•Human dietary supplement grade.

•Animal grade.

And we have two Kinds of Specifications of PEA:

1):Palmitoylethanolamide(PEA) flake

2):Palmitoylethanolamide(PEA)  ultra micronized powder (30micron)

3): Palmitoylethanolamide(PEA) granule powder

 

         

Product Name:	Palmitoylethanolamide,PEA
CAS Number:	544-31-0
Purity:	99%min
Appearance:	White ultra micro Powder(100% less than 20μm)
Speciality:	1：No use of any chemical solvents during production. (the only one company which has this special production technology.) 2:Made from Palm oil,Green and friendly for people. 3：No any chemical solvents residues. 4：More than 99% purity,Healthier for Human.(Tested by USA third party lab) 5:Special particle size, Higher absorption efficiency. 6:Our own brand for quality ensurance.( Opti-PEAactive® is our registered trade mark for our PEA)
Delivery:	Right away from stock.
Production ability:	5mt per month.
Usage:	1：Dietary Supplement for Human. 2：Nutritional Supplement for dogs and cats.

 

Introduction: Palmitoylethanolamide(PEA) is an endogenous fattyacid amide, belonging to the class of nuclear factor agonists. PEA is one of themost important endogenous painkilling and anti-inflammatory compounds and has been shown to effective for both acute and chronic pain. Because the substanceacts as a natural painkiller, it is an excellent alternative for conventionalmedications that might cause side effects.

 

2:Functions:

1. Anti-Inflammatory and Analgesic;

2. Improve the ability of immunity;

3. Treating chronic pain;

4. Treating epilepsy, cerebral ischemia and stroke;

5. Treating Alzheimer's disease and Parkinson's disease.

Application: As dietary supplement.

Storage: Stored in a cool and drycondition, get away from direct sun.

Shelf Life: 2 years if stored properly.

 

 

 

3: Why choose GIHI Palmitoylethanolamide:

• 1:High purity---99%+
• 2:Expert experience:We are the biggest manufacturer of Palmitoylethanolamide(PEA).We prouduced this product since 2011.
• 3:Our own patent production method:No any solvents during the production.
• So,our Palmitoylethanolamide (PEA) is the much more healthier .
• 4:Most of European and USA companies who is doing businees on this product all our customers.
• 5:USA Third Party Lab Test Report available
• 6:Stable stock:5000KG -10000KG every month
• 7:Professional technical service available

 

Most of our customers use our Palmitoylethanolamide(PEA) to make PEA capsule for human as dietary supplement. Some of our old customers used it for animal usage. The main formulation of PEA for human is :400mg/capsule,also some formulation is 350mg/capsule.

And some cusotmers make it into tablet ,and sevarl customers make cream to kill-pian cooperated with PEA capsule.

 

 

4:  Palmitoylethanolamide (PEA) Overview

Palmitoylethanolamide (PEA), an endogenous fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. The compound was used many decades ago in other countries, but since the 1990s, interest has surged again. It is classified as a food for medical purposes or as a diet supplement in various countries of Europe.

 

PEA has shown effectiveness in many different preclinical animal studies for chronic and neuropathic pain, and most importantly effectiveness in reducing pain in various human clinical trials. Human studies demonstrate PEA to be effective for different types of pain, including nerve pain, inflammatory pain and visceral pain such as endometriosis and interstitial cystitis. Clinical benefits have been shown for fibromyalgia, peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia, and rectal and vaginal pains.

 

Probably related to the fact that PEA is endogenous (manufactured by the body) and a compound found in foods such as eggs and milk, no serious side effects or drug–drug interactions been identified.

 

For more clinical information and information on formulations,

See Palmitoylethanolamide (PEA)

 

References

Palmitoylethanolamide4Pain.com

 

PEA – Availability

PEACure

PeaPure

 

Palmitoylethanolamide (PEA)

PEA – Overview

Information for MDs and Pharmacists on Palmitoylethanolmide

Chronic Pain in the Elderly – The Case for New Therapeutic Strategies – 2015

Palmitoylethanolamide for the treatment of pain – pharmacokinetics, safety and efficacy

Food-Derived Natural Compounds for Pain Relief in Neuropathic Pain – 2016

Palmitoylethanolamide – A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold – 2013

Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain – A Pooled Data Meta-analysis – 2016

Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. 2012 – PubMed – NCBI

N-palmitoyl-ethanolamine – Biochemistry and new therapeutic opportunities – 2010

 

PEA– Anxiety and Depression

Effects of palmitoylethanolamide and luteolin in an animal model of anxiety:depression. – PubMed – NCBI

 

PEA – Colds and Flu

Palmitoylethanolamide – A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold – 2013

 

PEA– Pain Conditions/Diagnoses

PEA– Arthritis

Degenerative Joint Diseases and Neuroinflammation – 2017

A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models – 2017

 

PEA – Back Pain

Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome – 2017

 

PEA – Carpal Tunnel and Nerve Comeprssion Syndromes

Use of palmitoylethanolamide in the entrapment neuropathy of the me… – PubMed – NCBI

Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes – efficacy and safety in sciatic pain and carpal tunnel syndrome – 2015

The carpal tunnel syndrome in diabetes – Clinical and electrophysiological improvement after treatment with palmitoylethanolamide. – 2010

Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrom – 2017

 

PEA– CRPS (Chronic Regional Pain Syndrome)

Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream – 2013

Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrom – 2017

 

PEA– Endometriosis

Micronized palmitoylethanolamide:trans – polydatin treatment of endometriosis-related pain – A meta-analysis – 2017

The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain – 2013

Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)- transpolydatin in the treatment of chronic pelvic pain related to endometriosis – 2011

 

PEA– Fibromyalgia

Palmitoylethanolamide in Fibromyalgia – Results from Prospective and Retrospective Observational Studies – 2015

 

PEA–Headaches (Migraine)

PeaPure – Palmitoylethanolamide for Nerve Pain or Migraine

 

PEA– Multiple Sclerosis

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokinesin Relapsing–Remitting Multiple Sclerosis – 2016

 

PEA – Proctodynia and Vulvodynia (Rectal and Vaginal Pain)

Vulvodynia & proctodynia treated with topical baclofen 5 % & palmitoylethanolamide | Pain Management Specialist in San Diego & La Jolla

 

PEA – Pudendal Neuralgia

Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to … – PubMed – NCBI

 

PEA – Pain Types/Mechanisms

 

PEA – Anti-inflammatory Mechanisms

Palmitoylethanolamide "PEA" – Review of Anti-inflammatory, Analgesic, Neuroprotective Mechanisms

Palmitoylethanolamide (PEA) – Boosting Its Anti-inflammatory Immune Response

 

PEA – Central Sensitivity, Oxidative Stress and Pain

Palmitoylethanolamide in CNS health and disease. – PubMed – NCBI

Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice – 2015

 

PEA – Morphine Tolerance

Delay of morphine tolerance by palmitoylethanolamide

 

PEA – Neuroinflammation, Glial Cells and Mast Cells

Emerging targets in neuroinflammation-driven chronic pain – 2014

Glia as a Link between Neuroinflammation and Neuropathic Pain – 2012

Importance of glial activation in neuropathic pain. – PubMed – NCBI

Mast cells, glia and neuroinflammation – partners in crime? – 2013

Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. – PubMed – NCBI

Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide – 2012

Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity – involvement of the CB2 receptor – 2017

Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility – 2003

N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. – PubMed – NCBI

 

PEA – Neuropathic Pain
Microglia in the spinal cord and neuropathic pain – 2016

Can modulating inflammatory response be a good strategy to treat neuropathic pain? – PubMed – NCBI

Chronic-idiopathic-axonal-neuropathy-and-pain–treated-with-PEA

Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. – PubMed – NCBI

Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy – Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism

Peroxisome proliferator-activated receptor agonists modulate neuropathic pain – 2014

Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain

Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients

Palmitoylethanolamide restores myelinated-fibre function in patient… – PubMed – NCBI

delay-of-morphine-tolerance-by-palmitoylethanolamide-2015

Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes – efficacy and safety in sciatic pain and carpal tunnel syndrome – 2015

Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome – 2017

Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. – PubMed – NCBI

N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. – PubMed – NCBI

Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain – A Pooled Data Meta-analysis – 2016

Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions – a case series – 2012

Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain – 2014

Comment on ''Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain'' – 2014

Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. – PubMed – NCBI

 

PEA – Visceral Pain, Endometriosis
The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain – 2013

Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)- transpolydatin in the treatment of chronic pelvic pain related to endometriosis – 2011

 

PEA – Products

PEA – Micronization Product Formulations

A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury

Micronization: a method of improving the bioavailability of poorly soluble drugs. – PubMed – NCBI

Safety of micronized palmitoylethanolamide (microPEA) – lack of toxicity and genotoxic potential – 2017

Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain – 2014

Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain –

study protocol for a series of N-of-1 randomized trials – 2015

Micronized palmitoylethanolamide:trans – polydatin treatment of endometriosis-related pain – A meta-analysis – 2017

 

PEA –Topical

Topical Analgesics – Critical Issues Related to Formulation and Concentration – 2016

Topical analgesic creams and nociception in diabetic neuropathy – towards a rationale fundament – 2016

 

 

5: FAQ

Q. Are you a trading company or a manufacturer?

A: We are the earliest and biggest manufacturer of PEA.

 

Q. What's the list of certificates you holds?

A: ISO9001:2008, FDA .

 

Q: Are you in stock?

A: Yes, regular products are in stock.

 

Q: Packaging & Shipping:

A: Bag and bucket, also be according to customer requirements.

 

Q:Can you provide the CoA and product description of the product?

A: We can provide CoA, sds ,tds,etc.

 

How To Buy

You can find us with this information:

GIHI CHEMICALS CO.,LIMITED
Tel:86-571-86217390

Mobile:86-18072806364

Fax:86-571-86089860

SKYPE:alice.gihichem
Facebook:gihichemicals@gmail.com
Twitter :gihichemicals@gmail.com
whatsapp:+86 18058761490

Email：sales@gihichemicals.com,sales@gihichem.com

Send us with your inquiry, we will reply you within 24 hours.